Sol-Gel Technologies Ltd., a clinical stage pharmaceutical company based in Israel, is making waves in the dermatological drug products market thanks to its unique microencapsulation delivery system. Since 1997, the company has been dedicated to developing and commercializing topical treatments for a range of skin conditions. Its proprietary technology has been utilized in a number of lead product candidates, including Twyneo—a novel, non-antibiotic, once-daily acne cream that has completed Phase III clinical trials—and Epsolay—a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea. Additionally, Sol-Gel Technologies Ltd. is currently conducting a Phase I clinical trial of SGT-210 for palmoplantar keratoderma and has completed Phase II clinical trials for SGT-610—a rare disease treatment for Gorlin Syndrome. The company is also developing generic topical dermatological drug products. Sol-Gel Technologies Ltd. has an ongoing collaboration with Perrigo, and its headquarters are located in Ness Ziona.